JP2019532080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532080A5 JP2019532080A5 JP2019520738A JP2019520738A JP2019532080A5 JP 2019532080 A5 JP2019532080 A5 JP 2019532080A5 JP 2019520738 A JP2019520738 A JP 2019520738A JP 2019520738 A JP2019520738 A JP 2019520738A JP 2019532080 A5 JP2019532080 A5 JP 2019532080A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- administered
- composition according
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 99
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 28
- 229960004397 cyclophosphamide Drugs 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000002552 dosage form Substances 0.000 claims description 23
- 239000003018 immunosuppressive agent Substances 0.000 claims description 21
- -1 temozolomid Chemical compound 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 229940121375 antifungal agent Drugs 0.000 claims description 17
- 239000003429 antifungal agent Substances 0.000 claims description 17
- 108090000695 Cytokines Proteins 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 15
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 15
- 229960004884 fluconazole Drugs 0.000 claims description 13
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 13
- 229960000390 fludarabine Drugs 0.000 claims description 13
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 229960001438 immunostimulant agent Drugs 0.000 claims description 7
- 239000003022 immunostimulating agent Substances 0.000 claims description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 3
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 3
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 3
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 3
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 claims description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 3
- 239000005822 Propiconazole Substances 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- 229950006816 albaconazole Drugs 0.000 claims description 3
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 claims description 3
- 229960000473 altretamine Drugs 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- 229960004022 clotrimazole Drugs 0.000 claims description 3
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003913 econazole Drugs 0.000 claims description 3
- 229960001274 fenticonazole Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004849 isoconazole Drugs 0.000 claims description 3
- 229960004130 itraconazole Drugs 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960002509 miconazole Drugs 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004031 omoconazole Drugs 0.000 claims description 3
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 claims description 3
- 229960003483 oxiconazole Drugs 0.000 claims description 3
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 229960001589 posaconazole Drugs 0.000 claims description 3
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 claims description 3
- 229960005429 sertaconazole Drugs 0.000 claims description 3
- 229960002607 sulconazole Drugs 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- 229940093257 valacyclovir Drugs 0.000 claims description 3
- 229960004740 voriconazole Drugs 0.000 claims description 3
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- ZMYFCFLJBGAQRS-IAGOWNOFSA-N (2S,3R)-epoxiconazole Chemical compound C1=CC(F)=CC=C1[C@]1(CN2N=CN=C2)[C@@H](C=2C(=CC=CC=2)Cl)O1 ZMYFCFLJBGAQRS-IAGOWNOFSA-N 0.000 claims 1
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010020326 Caspofungin Proteins 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 235000014150 Myroxylon pereirae Nutrition 0.000 claims 1
- 244000302151 Myroxylon pereirae Species 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000270295 Serpentes Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000009613 breast lymphoma Diseases 0.000 claims 1
- 229960005074 butoconazole Drugs 0.000 claims 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims 1
- 229960003034 caspofungin Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 102000006834 complement receptors Human genes 0.000 claims 1
- 108010047295 complement receptors Proteins 0.000 claims 1
- 108010027437 compstatin Proteins 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229940014456 mycophenolate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims 1
- 229960004313 naftifine Drugs 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002722 terbinafine Drugs 0.000 claims 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 96
- 238000012360 testing method Methods 0.000 description 42
- 239000000022 bacteriostatic agent Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 108091033409 CRISPR Proteins 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 10
- 239000013043 chemical agent Substances 0.000 description 10
- 238000010354 CRISPR gene editing Methods 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 7
- 108010042407 Endonucleases Proteins 0.000 description 6
- 102000004533 Endonucleases Human genes 0.000 description 6
- 108010063738 Interleukins Proteins 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000012009 microbiological test Methods 0.000 description 6
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 6
- 229960004448 pentamidine Drugs 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 229960005404 sulfamethoxazole Drugs 0.000 description 6
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 6
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical group COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 6
- 229960001082 trimethoprim Drugs 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 150000003851 azoles Chemical class 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960005310 aldesleukin Drugs 0.000 description 4
- 108700025316 aldesleukin Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 239000000417 fungicide Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000004291 polyenes Chemical class 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 101150069031 CSN2 gene Proteins 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 2
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 2
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 101150055601 cops2 gene Proteins 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 229960003937 efinaconazole Drugs 0.000 description 2
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 101150043532 CISH gene Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022792A JP2022059055A (ja) | 2016-10-18 | 2022-02-17 | 腫瘍浸潤リンパ球および治療の方法 |
| JP2022135735A JP2022162155A (ja) | 2016-10-18 | 2022-08-29 | 腫瘍浸潤リンパ球および治療の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409651P | 2016-10-18 | 2016-10-18 | |
| US62/409,651 | 2016-10-18 | ||
| US201762452244P | 2017-01-30 | 2017-01-30 | |
| US62/452,244 | 2017-01-30 | ||
| PCT/US2017/057228 WO2018075664A1 (en) | 2016-10-18 | 2017-10-18 | Tumor infiltrating lymphocytes and methods of therapy |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022792A Division JP2022059055A (ja) | 2016-10-18 | 2022-02-17 | 腫瘍浸潤リンパ球および治療の方法 |
| JP2022135735A Division JP2022162155A (ja) | 2016-10-18 | 2022-08-29 | 腫瘍浸潤リンパ球および治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532080A JP2019532080A (ja) | 2019-11-07 |
| JP2019532080A5 true JP2019532080A5 (enExample) | 2021-07-26 |
| JP7181862B2 JP7181862B2 (ja) | 2022-12-01 |
Family
ID=62019385
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520738A Active JP7181862B2 (ja) | 2016-10-18 | 2017-10-18 | 腫瘍浸潤リンパ球および治療の方法 |
| JP2022022792A Pending JP2022059055A (ja) | 2016-10-18 | 2022-02-17 | 腫瘍浸潤リンパ球および治療の方法 |
| JP2022135735A Pending JP2022162155A (ja) | 2016-10-18 | 2022-08-29 | 腫瘍浸潤リンパ球および治療の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022792A Pending JP2022059055A (ja) | 2016-10-18 | 2022-02-17 | 腫瘍浸潤リンパ球および治療の方法 |
| JP2022135735A Pending JP2022162155A (ja) | 2016-10-18 | 2022-08-29 | 腫瘍浸潤リンパ球および治療の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10912797B2 (enExample) |
| EP (2) | EP3529359B1 (enExample) |
| JP (3) | JP7181862B2 (enExample) |
| CN (1) | CN110520530A (enExample) |
| AU (2) | AU2017346885B2 (enExample) |
| CA (1) | CA3041068A1 (enExample) |
| GB (4) | GB2573406B (enExample) |
| WO (1) | WO2018075664A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| EP3299030B1 (en) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| GB2557123B (en) | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| GB2573406B (en) * | 2016-10-18 | 2021-11-10 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| BR112020008568A2 (pt) * | 2017-11-09 | 2020-10-06 | Sangamo Therapeutics, Inc. | modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish) |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| EP3784254A1 (en) * | 2018-04-27 | 2021-03-03 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20210254068A1 (en) * | 2018-06-19 | 2021-08-19 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| CN116144706A (zh) | 2018-08-13 | 2023-05-23 | 根路径基因组学公司 | 成对的二分免疫受体多核苷酸的高通量克隆及其应用 |
| EP3852524B1 (en) * | 2018-09-20 | 2023-06-28 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
| EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
| EP3947436A4 (en) | 2019-04-05 | 2022-12-28 | Rootpath Genomics, Inc. | COMPOSITIONS AND METHODS FOR ASSEMBLING T LYMPHOCYTE RECEPTOR GENE |
| US12188045B2 (en) | 2019-06-07 | 2025-01-07 | KSQ Therapeutics, Inc. | Guide RNA combinations and methods of use |
| AU2020304022A1 (en) * | 2019-06-24 | 2022-02-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes |
| KR102902719B1 (ko) | 2019-10-18 | 2025-12-24 | 포티 세븐, 엘엘씨 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| WO2021081378A1 (en) * | 2019-10-25 | 2021-04-29 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN110628717B (zh) * | 2019-10-28 | 2020-10-30 | 上海科医联创生物科技有限公司 | 一种浸润性t细胞的培养方法 |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CA3162896A1 (en) * | 2019-11-27 | 2021-06-03 | Board Of Regents, The University Of Texas System | Engineered t cells and tumor-infiltrating lymphocytes to overcome immunosuppression in the tumor microenvironment |
| BR112022011702A2 (pt) * | 2019-12-18 | 2022-09-06 | Cbio As | Processo melhorado para cultura de linfócitos infiltrantes tumorais para uso terapêutico |
| KR20220119439A (ko) | 2019-12-20 | 2022-08-29 | 인스틸 바이오 유케이 리미티드 | 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도 |
| EP4445902A3 (en) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN116018158A (zh) * | 2020-04-30 | 2023-04-25 | 转化基因组学研究所 | 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法 |
| KR20230040348A (ko) * | 2020-07-15 | 2023-03-22 | 더 잭슨 래보라토리 | Sars-cov-2 감염에 대한 인간화 마우스 모델 |
| WO2022082216A1 (en) * | 2020-10-14 | 2022-04-21 | Loma Linda Faculty Medical Group | Combination of adoptive cell therapy and chemotherapy for acute myeloid leukemia |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| WO2022125633A1 (en) * | 2020-12-08 | 2022-06-16 | The Regents Of The University Of California | Crispr ribonucleoprotein complex genome editing of human innate immune cells |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022192536A1 (en) * | 2021-03-11 | 2022-09-15 | The Methodist Hospital | Methods and compositions for treatment of disease |
| JP2024511414A (ja) * | 2021-03-23 | 2024-03-13 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240052771A (ko) * | 2021-09-08 | 2024-04-23 | 케이에스큐 세러퓨틱스 인코포레이티드 | 림프구 효력 검정 |
| CN113952475B (zh) * | 2021-09-27 | 2025-03-11 | 中国人民解放军陆军军医大学 | 淋巴细胞和介导crispr系统的纳米复合物联合在制备治疗宫颈癌药物中的应用 |
| CN118525084A (zh) * | 2022-01-19 | 2024-08-20 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞在疾病治疗中的用途 |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2025096638A2 (en) * | 2023-10-30 | 2025-05-08 | Turnstone Biologics Corp. | Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025250550A1 (en) * | 2024-05-28 | 2025-12-04 | Ctrl Therapeutics Usa, Inc. | Enhanced expansion of tumor-reactive lymphocytes for cancer treatment |
Family Cites Families (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| WO1998006746A2 (en) | 1996-08-16 | 1998-02-19 | The Johns Hopkins University School Of Medicine | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same |
| DE69718029T2 (de) | 1996-10-11 | 2003-10-16 | The Regents Of The University Of California, Oakland | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| US6323317B1 (en) * | 1996-11-01 | 2001-11-27 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic and diagnostics proteins comprising a SOCS box |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2002535995A (ja) | 1999-02-03 | 2002-10-29 | ザ チルドレンズ メディカル センター コーポレイション | 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復 |
| JP2000256212A (ja) * | 1999-03-05 | 2000-09-19 | Tadayasu Takada | 良性間葉系腫瘍の治療剤 |
| EP2311951A1 (en) | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| EP1330156A4 (en) | 2000-10-09 | 2006-09-13 | Amrad Operations Pty Ltd | MODULATION OF CYTOKINE OR HORMONE SIGNALING IN AN ANIMAL, INTEGRATING PROGRESSIVE REGULATION OF SOCS SEQUENCE EXPRESSION IN ANIMALS |
| US8716022B2 (en) | 2000-11-17 | 2014-05-06 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Modulation of meiotic recombination |
| US7723111B2 (en) | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| MXPA04001974A (es) | 2001-08-31 | 2004-07-16 | Avidex Ltd | Receptor de celula t soluble. |
| EP2034009B1 (en) | 2002-02-08 | 2014-01-15 | Life Technologies Corporation | Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1517992B1 (en) | 2002-06-05 | 2013-08-21 | Her Majesty the Queen in Right of Canada, as represented by the Minister of Agriculture and Agri-Food | Retrons for gene targeting |
| US8034334B2 (en) * | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| HUE054805T2 (hu) | 2003-09-30 | 2021-09-28 | Univ Pennsylvania | Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| EP1756278B1 (en) | 2004-05-19 | 2008-09-17 | MediGene Ltd. | Method of improving t cell receptors |
| JP4773434B2 (ja) | 2004-05-19 | 2011-09-14 | イムノコア リミテッド | 高親和性ｎｙ−ｅｓｏｔ細胞受容体 |
| WO2006112869A2 (en) | 2004-07-19 | 2006-10-26 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
| US8889365B2 (en) | 2005-03-16 | 2014-11-18 | Rutgers, The State University Of New Jersey | Methods and kit for detecting breast cancer |
| EP3085389A1 (en) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| US8389708B2 (en) | 2005-06-15 | 2013-03-05 | Weiping Min | Method of cancer treatment using siRNA silencing |
| DK1910521T3 (da) | 2005-08-05 | 2011-02-07 | Helmholtz Zentrum Muenchen | Generering af allo-begrænsede, antigenspecifikke T-celler |
| NZ597299A (en) | 2005-08-26 | 2013-03-28 | Dupont Nutrition Biosci Aps | Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell |
| US20090220488A1 (en) * | 2005-08-31 | 2009-09-03 | Humphrey Gardner | Evaluating and treating scleroderma |
| ES2543629T3 (es) | 2006-05-17 | 2015-08-20 | Hoffmann-La Roche Ag | Células productoras de polipéptidos |
| US9399801B2 (en) | 2006-05-19 | 2016-07-26 | Dupont Nutrition Biosciences Aps | Tagged microorganisms and methods of tagging |
| EP1878744A1 (en) | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| US7750449B2 (en) | 2007-03-13 | 2010-07-06 | Micron Technology, Inc. | Packaged semiconductor components having substantially rigid support members and methods of packaging semiconductor components |
| PL2856876T3 (pl) | 2007-03-30 | 2018-06-29 | Memorial Sloan-Kettering Cancer Center | Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US20120192298A1 (en) | 2009-07-24 | 2012-07-26 | Sigma Aldrich Co. Llc | Method for genome editing |
| US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011117258A2 (en) | 2010-03-22 | 2011-09-29 | Association Institut De Myologie | Methods of increasing efficiency of vector penetration of target tissue |
| KR102095670B1 (ko) * | 2010-05-14 | 2020-03-31 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| JP5261448B2 (ja) * | 2010-08-09 | 2013-08-14 | 古河電気工業株式会社 | 空孔アシスト光ファイバ |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| WO2012078540A1 (en) | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012112079A1 (en) | 2011-02-14 | 2012-08-23 | Vitaspero, Inc. | IMPROVING CELLULAR IMMUNOTHERAPEUTIC VACCINES EFFICACY WITH GENE SUPPRESSION IN DENDRITIC CELLS AND T-LYMPHOCYTES USING SiRNA |
| US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP3219313B1 (en) | 2011-04-18 | 2020-10-28 | National Center of Neurology and Psychiatry | Drug delivery particle and method for producing the same |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| US9096642B2 (en) | 2011-06-08 | 2015-08-04 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| KR101307196B1 (ko) | 2011-07-15 | 2013-09-12 | 국립대학법인 울산과학기술대학교 산학협력단 | 미세 세포 배양 장치 |
| US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| WO2013049330A1 (en) | 2011-09-28 | 2013-04-04 | The Regents Of The University Of California | Synthetic transcriptional control elements and methods of generating and using such elements |
| US9279159B2 (en) | 2011-10-21 | 2016-03-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| US9688740B2 (en) | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP2790708B1 (en) | 2011-12-16 | 2024-10-23 | Targetgene Biotechnologies Ltd. | Compositions and methods for modifying a predetermined target nucleic acid sequence |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| CN104507963B (zh) | 2012-05-22 | 2017-12-15 | 美国卫生和人力服务部 | 鼠抗‑ny‑eso‑1 t细胞受体 |
| EP4541818A3 (en) | 2012-05-25 | 2025-07-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| US9969696B2 (en) | 2012-07-04 | 2018-05-15 | Indian Institute Of Science | Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof |
| JP2015527889A (ja) | 2012-07-25 | 2015-09-24 | ザ ブロード インスティテュート， インコーポレイテッド | 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用 |
| WO2014022702A2 (en) | 2012-08-03 | 2014-02-06 | The Regents Of The University Of California | Methods and compositions for controlling gene expression by rna processing |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US20140113375A1 (en) | 2012-10-21 | 2014-04-24 | Lixin Liu | Transient Expression And Reverse Transcription Aided Genome Alteration System |
| PL4397760T3 (pl) | 2012-10-23 | 2026-03-30 | Toolgen Incorporated | Kompozycja do rozszczepiania docelowego dna zawierająca prowadzące rna specyficzne dla docelowego dna i kwas nukleinowy kodujący białko cas lub białko cas oraz jej zastosowanie |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP3135765A1 (en) | 2012-12-06 | 2017-03-01 | Sigma-Aldrich Co. LLC | Crispr-based genome modification and regulation |
| EP2896697B1 (en) | 2012-12-12 | 2015-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| JP2016504026A (ja) | 2012-12-12 | 2016-02-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための系、方法および最適化ガイド組成物のエンジニアリング |
| ES2576126T3 (es) | 2012-12-12 | 2016-07-05 | The Broad Institute, Inc. | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CN114634950A (zh) | 2012-12-12 | 2022-06-17 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| SG10201912991WA (en) | 2012-12-17 | 2020-03-30 | Harvard College | Rna-guided human genome engineering |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| EP2958996B1 (en) | 2013-02-25 | 2019-10-16 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| BR112015020516A2 (pt) | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| US9393257B2 (en) | 2013-03-01 | 2016-07-19 | Regents Of The University Of Minnesota | TALEN-based gene correction |
| WO2014153118A1 (en) | 2013-03-14 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| SG11201507378UA (en) | 2013-03-14 | 2015-10-29 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US10378027B2 (en) | 2013-03-15 | 2019-08-13 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用 |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| RU2725542C2 (ru) | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
| EP3730615A3 (en) | 2013-05-15 | 2020-12-09 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
| ES2670531T3 (es) | 2013-05-29 | 2018-05-30 | Cellectis S.A. | Un método para producir una escisión de ADN precisa utilizando la actividad nickasa de Cas9 |
| DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| JP6195474B2 (ja) | 2013-05-31 | 2017-09-13 | ギガフォトン株式会社 | 極端紫外光生成装置及び極端紫外光生成システムにおけるレーザシステムの制御方法 |
| JP6665088B2 (ja) | 2013-06-17 | 2020-03-13 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物 |
| MX2015017312A (es) | 2013-06-17 | 2017-04-10 | Broad Inst Inc | Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas. |
| WO2014204724A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| CN105793425B (zh) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
| EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| JP6738729B2 (ja) | 2013-06-17 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化 |
| WO2015002293A1 (ja) * | 2013-07-05 | 2015-01-08 | 学校法人岩手医科大学 | Ｗｎｔシグナル阻害剤 |
| JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用 |
| BR112016000571B1 (pt) | 2013-07-10 | 2023-12-26 | President And Fellows Of Harvard College | Métodos in vitro para modular a expressão e para alterar um ou mais ácidos nucleicos alvo em uma célula simultaneamente com a regulação da expressão de um ou mais ácidos nucleicos alvo em uma célula, bem como célula de levedura ou bactéria compreendendo ácidos nucleicos |
| US20150020233A1 (en) | 2013-07-12 | 2015-01-15 | Oms Investments, Inc. | Plants comprising events pp009-401, pp009-415, and pp009-469, compositions, sequences, and methods for detection thereof |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| US20150044772A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| CA3221516A1 (en) | 2013-08-22 | 2015-02-26 | E. I. Du Pont De Nemours And Company | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
| CN104427476B (zh) | 2013-09-10 | 2019-05-07 | 中兴通讯股份有限公司 | 位置信息上报方法、集群服务处理方法及系统 |
| WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| WO2015048690A1 (en) | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Optimized small guide rnas and methods of use |
| US20150098954A1 (en) | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
| DE102013111099B4 (de) | 2013-10-08 | 2023-11-30 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA |
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| JP2016538001A (ja) | 2013-11-28 | 2016-12-08 | ホライズン・ジェノミクス・ゲーエムベーハー | 体細胞半数体ヒト細胞株 |
| CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| BR112016013213A2 (pt) | 2013-12-12 | 2017-12-05 | Massachusetts Inst Technology | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas |
| CN103820454B (zh) | 2014-03-04 | 2016-03-30 | 上海金卫生物技术有限公司 | CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| MX374472B (es) * | 2014-03-20 | 2025-03-06 | H Lee Moffitt Cancer Ct & Res | Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. |
| EP3129490A4 (en) | 2014-04-08 | 2017-10-04 | North Carolina State University | Methods and compositions for rna-directed repression of transcription using crispr-associated genes |
| WO2015157534A1 (en) | 2014-04-10 | 2015-10-15 | The Regents Of The University Of California | Methods and compositions for using argonaute to modify a single stranded target nucleic acid |
| KR102595473B1 (ko) | 2014-04-18 | 2023-10-30 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
| IL313845A (en) | 2014-04-23 | 2024-08-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| EP3151846A4 (en) | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
| US20170224731A1 (en) | 2014-06-10 | 2017-08-10 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| WO2015191693A2 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| TWI530276B (zh) | 2014-07-08 | 2016-04-21 | 原相科技股份有限公司 | 具去噪功能之生理偵測模組及其生理偵測方法 |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| JP2017522884A (ja) * | 2014-07-29 | 2017-08-17 | ファイザー・インク | がん免疫療法のためのＥＧＦＲｖＩＩＩ特異的キメラ抗原受容体 |
| IL287561B2 (en) | 2014-10-01 | 2024-03-01 | Massachusetts Gen Hospital | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| CN107074932A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| KR20170075013A (ko) | 2014-10-31 | 2017-06-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cart 세포에서 유전자 발현의 변경 및 그의 용도 |
| WO2016089433A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| CA2972454C (en) | 2014-12-31 | 2024-09-10 | Phykion Inc. | Compositions and methods for high efficiency in in vivo genome editing |
| US10280451B2 (en) | 2015-01-09 | 2019-05-07 | Bio-Rad Laboratories, Inc. | Detection of genome editing |
| CN107429263A (zh) | 2015-01-15 | 2017-12-01 | 斯坦福大学托管董事会 | 调控基因组编辑的方法 |
| KR102422108B1 (ko) | 2015-01-20 | 2022-07-19 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| EP3294343A4 (en) | 2015-05-13 | 2018-09-26 | Seattle Children's Hospital, dba Seattle Children's Research Institute | Enhancing endonuclease based gene editing in primary cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CN108024544B (zh) | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的基因组工程化的递送方法及组合物 |
| GB2557123B (en) | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| JP2019505498A (ja) | 2015-12-16 | 2019-02-28 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害 |
| US9570114B1 (en) | 2016-01-15 | 2017-02-14 | HGST Netherlands B.V. | Laminated film-packed hard disk drive for hermetic sealing |
| US11746349B2 (en) | 2016-02-09 | 2023-09-05 | President And Fellows Of Harvard College | DNA-guided gene editing and regulation |
| MX2019000149A (es) * | 2016-07-07 | 2019-09-23 | Iovance Biotherapeutics Inc | Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas. |
| GB2573406B (en) * | 2016-10-18 | 2021-11-10 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| CN111344396A (zh) | 2016-10-27 | 2020-06-26 | 因提玛生物科学公司 | 制备遗传修饰细胞的病毒方法 |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| CN111836891A (zh) | 2017-09-07 | 2020-10-27 | 莱兰斯坦福初级大学评议会 | 用于基因工程的核酸酶系统 |
-
2017
- 2017-10-18 GB GB1906855.0A patent/GB2573406B/en active Active
- 2017-10-18 JP JP2019520738A patent/JP7181862B2/ja active Active
- 2017-10-18 GB GB2205417.5A patent/GB2605883B/en active Active
- 2017-10-18 AU AU2017346885A patent/AU2017346885B2/en active Active
- 2017-10-18 CN CN201780078471.6A patent/CN110520530A/zh active Pending
- 2017-10-18 CA CA3041068A patent/CA3041068A1/en active Pending
- 2017-10-18 GB GB2113770.8A patent/GB2604416B/en active Active
- 2017-10-18 GB GB2209032.8A patent/GB2605540B/en active Active
- 2017-10-18 EP EP17861792.4A patent/EP3529359B1/en active Active
- 2017-10-18 WO PCT/US2017/057228 patent/WO2018075664A1/en not_active Ceased
- 2017-10-18 EP EP23211578.2A patent/EP4338799A3/en not_active Withdrawn
-
2018
- 2018-04-06 US US15/947,688 patent/US10912797B2/en active Active
-
2020
- 2020-05-28 US US16/885,882 patent/US20200289571A1/en not_active Abandoned
- 2020-05-28 US US16/885,874 patent/US11154574B2/en active Active
- 2020-06-02 US US16/889,914 patent/US20200330517A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/481,404 patent/US20220105133A1/en active Pending
-
2022
- 2022-01-17 AU AU2022200267A patent/AU2022200267A1/en not_active Abandoned
- 2022-02-17 JP JP2022022792A patent/JP2022059055A/ja active Pending
- 2022-08-29 JP JP2022135735A patent/JP2022162155A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022162155A5 (enExample) | ||
| EP3957644B1 (en) | Cancer immunotherapy using virus particles | |
| JP2019534308A5 (enExample) | ||
| US10016421B2 (en) | Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| JP2024540994A5 (enExample) | ||
| JP2019500055A (ja) | 改変された免疫細胞およびその使用 | |
| EP3411497A1 (en) | Copanlisib biomarkers | |
| WO2014089029A1 (en) | Activation of innate immunity by mirna for cancer and infection treatment | |
| US20240065987A1 (en) | Anti-cancer activity of adamantane derivatives | |
| EP3436071A1 (en) | Combinational uses of nitroxoline and its analogues with chemotherapeis and immunotherapies in the treatment of cancers | |
| US20230106313A1 (en) | A bacterial composition for the treatment of cancer | |
| JP6702938B2 (ja) | アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用 | |
| WO2018053270A1 (en) | Modified natural killer cells for the treatment of cancer | |
| CN113440533B (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| Nisar et al. | Immuno-oncological challenges and chemoresistance in veterinary medicine: probiotics as a new strategic tool | |
| WO2025025480A1 (zh) | 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒 | |
| US20210308106A1 (en) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis | |
| WO2020242910A1 (en) | Compositions and methods for treating cancer | |
| JP2021533107A (ja) | 癌を治療するための併用療法 | |
| WO2024238486A2 (en) | Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer | |
| WO2024064764A2 (en) | Methods for treating cancer using a stat3 double-stranded, cyclic oligonucleotide decoy | |
| WO2025063844A1 (en) | Enhancement of t cell mediated therapies with a dna hypomethylating agent and a sumoylation inhibitor | |
| CN118903431A (zh) | Itgb4/bnip3信号轴阻断剂在制备胰腺癌免疫治疗药物中的应用 | |
| CN121772932A (zh) | 抑制GvHD的树突状细胞群 |